Capricor Therapeutics: FDA Advisory Meeting for Duchenne Therapy on the Horizon
Capricor Therapeutics seeks FDA approval for Deramiocel, a promising cell therapy for Duchenne muscular dystrophy, backed by five-year data.
Sienna Senior Living Expands Portfolio with Rockland Manor Acquisition
Sienna Senior Living's acquisition of Rockland Manor highlights strategic growth in the senior livin…
Calian Group Expands Reach with Galaxy Broadband Acquisition
Calian Group is set to enhance its market presence with the acquisition of Galaxy Broadband for up t…
Everlert's MOU for Rimrock Project: A Step Towards Critical Mineral Development
Everlert Inc. has signed an MOU to acquire the Rimrock Copper-Gold Project, highlighting the importa…
Luna Innovations to Go Private: Implications for Investors and the Defense Sector
Luna Innovations is set to be acquired by TJC, raising questions about market visibility and investo…
Replimune's FDA BLA Resubmission: A Game-Changer for Biotech Investors
Replimune's resubmission acceptance by the FDA could redefine investor sentiment and market dynamics…
Citi Analysts Weigh in on ON Semiconductor's Potential Acquisition of Synaptics
Citi analysts assess ON Semiconductor's acquisition of Synaptics, highlighting potential AI benefits…
Aptorum Group's Strategic Move in Alzheimer's Biomarkers: A Game Changer for Investors?
Aptorum Group's collaboration with AlzLabs could reshape Alzheimer's diagnostics and impact the smal…
SpaceX's Bond Sale: A Strategic Move Amidst Massive Cash Reserves
SpaceX's recent bond sale comes as it holds $100.8 billion in cash, reflecting strategic capital mar…
AbbVie’s $10.9 Billion Bet on Apogee: What It Means for Investors
AbbVie's $10.9 billion acquisition of Apogee Therapeutics reshapes its pipeline and reflects broader…